OPKO Health, Inc. (NASDAQ:OPK) Shares Sold by Centiva Capital LP

Centiva Capital LP decreased its position in OPKO Health, Inc. (NASDAQ:OPK) by 65.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 35,838 shares of the biotechnology company’s stock after selling 66,422 shares during the period. Centiva Capital LP’s holdings in OPKO Health were worth $53,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Clearline Capital LP purchased a new position in shares of OPKO Health during the 3rd quarter worth approximately $1,083,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in OPKO Health during the 3rd quarter valued at $138,000. Verition Fund Management LLC purchased a new position in OPKO Health during the third quarter worth $201,000. Rubric Capital Management LP raised its holdings in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after acquiring an additional 4,284,336 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 217,450 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The stock was acquired at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the acquisition, the chief executive officer now directly owns 211,612,405 shares in the company, valued at approximately $342,812,096.10. This represents a 0.05 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders have purchased a total of 1,304,255 shares of company stock worth $2,024,605 in the last three months. Company insiders own 47.26% of the company’s stock.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.59 on Friday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.09 billion, a PE ratio of -8.37 and a beta of 1.62. The business’s 50-day moving average price is $1.53 and its 200 day moving average price is $1.47. OPKO Health, Inc. has a twelve month low of $0.85 and a twelve month high of $1.76.

Wall Street Analyst Weigh In

A number of research firms recently commented on OPK. Piper Sandler reiterated an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.